actinium has been researched along with lutetium in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 8 (57.14) | 2.80 |
| Authors | Studies |
|---|---|
| Linzner, U; Luz, A; Müller, WA; Schäffer, EH | 1 |
| Anderson, T; Atcher, R; Nayak, T; Norenberg, J | 1 |
| Bruchertseifer, F; Fahrer, J; Fottner, C; Graf, F; Huelsenbeck, J; Kaina, B; Maus, S; Miederer, M; Morgenstern, A; Schreckenberger, M; Venkatachalam, S; Weber, MM | 1 |
| Amor-Coarasa, A; Babich, JW; Kelly, JM; Kim, D; Nikolopoulou, A; Vallabhajosula, S; Williams, C | 1 |
| Bednarz, B; Lee, D; Li, M; Schultz, MK | 1 |
| Aranda-Lara, L; Azorín-Vega, E; Ferro-Flores, G; Jiménez-Mancilla, N; Nava-Cabrera, MA; Rojas-Calderón, E | 1 |
| Allen, KJH; Dadachova, E; de Klerk, JMH; Helal, M; Lam, MGEH; van der Wal, BCH; van Dijk, B; Vogely, HC; Weinans, H | 1 |
| Abergel, RJ; An, DD; Ansoborlo, C; Gauny, SS; Karsunky, H; Lakes, AL; Liang, BH; McKnight, KD; Rees, JA | 1 |
| Beheshti, A; Bruchertseifer, F; D'Alessandria, C; Eiber, M; Feuerecker, B; Gafita, A; Gschwend, JE; Heck, M; Knorr, K; Kratochwil, C; Morgenstern, A; Pickhard, A; Retz, M; Seidl, C; Tauber, R; Weber, WA | 1 |
| Aranda-Lara, L; Azorín-Vega, E; Nava-Cabrera, M; Oros-Pantoja, R | 1 |
| Kim, YI; Lee, DY | 1 |
| Afshar-Oromieh, A; Birindelli, G; D'Alessandria, C; Drobnjakovic, M; Eiber, M; Gourni, E; Morath, V; Rominger, A; Shi, K; Steiger, K; Weber, W | 1 |
| Gill, HJS; Maheshwari, P; Satapathy, S; Sharma, A; Sood, A | 1 |
| de Blois, E; de Jong, M; De Saint-Hubert, M; Konijnenberg, MW; Nonnekens, J; Roobol, SJ; Ruigrok, EAM; Tamborino, G; van Weerden, WM; Verkaik, N | 1 |
1 review(s) available for actinium and lutetium
| Article | Year |
|---|---|
Effects of
Topics: Actinium; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Leukopenia; Lutetium; Male; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Thrombocytopenia; Treatment Outcome; Xerostomia | 2022 |
13 other study(ies) available for actinium and lutetium
| Article | Year |
|---|---|
Incorporation experiments with combined application of different bone seekers.
Topics: Actinium; Animals; Body Burden; Bone and Bones; Bone Neoplasms; Cocarcinogenesis; Dose-Response Relationship, Radiation; Lutetium; Mice; Neoplasms, Radiation-Induced; Neptunium; Osteosarcoma; Plutonium; Radioisotopes | 1984 |
A comparison of high- versus low-linear energy transfer somatostatin receptor targeted radionuclide therapy in vitro.
Topics: Actinium; Alpha Particles; Apoptosis; Beta Particles; Bismuth; Cell Line, Tumor; Cell Nucleus; Cell Survival; Dose-Response Relationship, Radiation; Energy Transfer; Enzyme-Linked Immunosorbent Assay; Humans; Ligands; Lutetium; Mitosis; Models, Statistical; Neoplasms; Octreotide; Radioisotopes; Radiometry; Radiopharmaceuticals; Receptors, Somatostatin | 2005 |
DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy.
Topics: Actinium; Alpha Particles; Animals; Cell Cycle; Cell Death; Cell Line, Tumor; DNA Breaks, Double-Stranded; Lutetium; Neuroendocrine Tumors; Radioisotopes; Rats; Receptors, Somatostatin | 2014 |
Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of
Topics: Actinium; Antigens, Surface; Cell Line, Tumor; Chelating Agents; Drug Stability; Gallium Radioisotopes; Glutamate Carboxypeptidase II; Humans; Indium Radioisotopes; Kinetics; Ligands; Lutetium; Positron-Emission Tomography; Radioisotopes | 2017 |
Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy.
Topics: Actinium; Alpha Particles; Beta Particles; Bismuth; Dose-Response Relationship, Radiation; Humans; Lead Radioisotopes; Lutetium; Neoplasm Metastasis; Neoplasms; Radioisotopes; Yttrium Radioisotopes | 2018 |
Assessment of the radiation absorbed dose produced by
Topics: Actinium; Antigens, Surface; Bone Neoplasms; Cell Line, Tumor; Cell Nucleus; Computer Simulation; Glutamate Carboxypeptidase II; Humans; Lutetium; Male; Models, Biological; Monte Carlo Method; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage; Radium; Tumor Microenvironment | 2019 |
Radioimmunotherapy of methicillin-resistant Staphylococcus aureus in planktonic state and biofilms.
Topics: Actinium; Antibodies, Monoclonal; Biofilms; Bismuth; Humans; In Vitro Techniques; Lutetium; Methicillin-Resistant Staphylococcus aureus; Plankton; Proof of Concept Study; Prosthesis-Related Infections; Radioimmunotherapy; Radioisotopes; Staphylococcal Infections; Teichoic Acids | 2020 |
Evaluating
Topics: Actinium; Alpha Particles; Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Benzodiazepines; Beta Particles; Female; HEK293 Cells; Humans; Immunoconjugates; Immunoglobulin G; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Lutetium; Maximum Tolerated Dose; Membrane Proteins; Mice; Mice, Inbred NOD; Mice, SCID; Pyrroles; Radioisotopes; Small Cell Lung Carcinoma; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2020 |
Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
Topics: Actinium; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome; Xerostomia | 2021 |
Comparison between
Topics: Actinium; Animals; Bone Neoplasms; Cell Line, Tumor; Disease Models, Animal; Humans; Lutetium; Mice, Nude; Neoplasm Metastasis; Radioisotopes; Radiometry | 2021 |
In silico study on radiobiological efficacy of Ac-225 and Lu-177 for PSMA-guided radiotherapy.
Topics: Actinium; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Tumor Microenvironment | 2021 |
Delayed Nephrotoxicity After 225Ac-PSMA-617 Radioligand Therapy.
Topics: Actinium; Aged; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2022 |
In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T.
Topics: Actinium; Cell Line, Tumor; Dipeptides; DNA; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes | 2022 |